Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 4,001–4,100 of 10,906
Clinical spectrum of gross haematuria following SARS-CoV-2 vaccination with mRNA vaccines
Ritter, A., Helmchen, B., Gaspert, A., Bleisch, J., Fritschi, B., Buchkremer, F., Damm, S., Schmid, N., Schachtner, T., & Seeger, H. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab284 · Cited by 18
Hatcher, S. M., Endres‐Dighe, S. M., Angulo, F. J., Srivastava, A. K., Nguyen, J. L., Khan, F. L., Martin, C., Swerdlow, D. L., McLaughlin, J. M., Ubaka-Blackmoore, N., et al. (2022) · Vaccines · doi:10.3390/vaccines10030393 · Cited by 20
Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients
Singer, J., Le, N., Mattes, D., Klamminger, V., Hackner, K., Kolinsky, N., Scherb, M., Errhalt, P., Kreye, G., Pecherstorfer, M., et al. (2021) · Cancers · doi:10.3390/cancers13174312 · Cited by 19
Beyond COVID-19: the promise of next-generation coronavirus vaccines
Mukesh, R. K., Yinda, C. K., Munster, V. J., & van Doremalen, N. (2024) · npj Viruses · doi:10.1038/s44298-024-00043-3 · Cited by 17
Hanafy, B. I., Munson, M. J., Soundararajan, R., Pereira, S. G. T., Gallud, A., Sanaullah, S. M., Carlesso, G., & Mazza, M. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202500383 · Cited by 32
Varón, L. S., González-Puelma, J., Medina-Ortiz, D., Aldridge, J., Álvarez-Saravia, D., Uribe-Paredes, R., & Navarrete, M. A. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1140353 · Cited by 23
Simulation of future COVID-19 epidemic by vaccination coverage scenarios in Japan
Furuse, Y. (2021) · Journal of Global Health · doi:10.7189/jogh.11.05025 · Cited by 17
New insights into human immune memory from SARS‐CoV ‐2 infection and vaccination
Hartley, G. E., Edwards, E. S. J., O’Hehir, R. E., & van Zelm, M. C. (2022) · Allergy · doi:10.1111/all.15502 · Cited by 17
Paediatric research in the times of COVID-19
Fleming, P., Gale, C. P., Molloy, E. J., Faust, S. N., Costeloe, K., Juszczak, E., & Roehr, C. C. (2021) · Pediatric Research · doi:10.1038/s41390-021-01479-6 · Cited by 18
Immunopeptidomics in the Era of Single-Cell Proteomics
Mayer, R. L., & Mechtler, K. (2023) · Biology · doi:10.3390/biology12121514 · Cited by 19
Aparicio, B., Casares, N., Egea, J., Ruiz, M., Llópiz, D., Maestro, S., Olagüe, C., González‐Aseguinolaza, G., Smerdou, C., de Cerio, A. L.-D., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1978823 · Cited by 17
Ringlander, J., Olausson, J., Nyström, K., Härnqvist, T., Jakobsson, H. E., & Lindh, M. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.1957143 · Cited by 15
Stauft, C. B., Selvaraj, P., D’Agnillo, F., Meseda, C. A., Liu, S., Pedro, C. L., Sangare, K., Lien, C. Z., Weir, J. P., Starost, M. F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39090-4 · Cited by 18
Testing and vaccination to reduce the impact of COVID-19 in nursing homes: an agent-based approach
Gómez-Vázquez, J. P., García, Y. E., Schmidt, A. J., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07385-4 · Cited by 16
Sølund, C. S., Underwood, A. P., Fernandez-Antunez, C., Bollerup, S., Mikkelsen, L. S., Villadsen, S. L., Fahnøe, U., Winckelmann, A. A., Feng, S., Vinten, C., et al. (2022) · Vaccines · doi:10.3390/vaccines10010075 · Cited by 17
Platelet Surface Protein Expression and Reactivity upon TRAP Stimulation after BNT162b2 Vaccination
Klug, M., Lazareva, O., Kirmes, K., Rosenbaum, M., Lukas, M., Weidlich, S., Spinner, C. D., von Scheidt, M., Gosetti, R., Baumbach, J., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/s-0041-1733934 · Cited by 16
Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany
Joshi, K., Scholz, S. M., Maschio, M., Kohli, M. A., Lee, A., Fust, K., Ultsch, B., de Velde, N. V., & Beck, E. C. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2290388 · Cited by 16
Bermingham, C. R., Morgan, J., Ayoubkhani, D., Glickman, M., Islam, N., Sheikh, A., Sterne, J. A. C., Walker, A. S., & Nafilyan, V. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac157 · Cited by 14
Roles of microRNAs in Gastrointestinal Cancer Stem Cell Resistance and Therapeutic Development
Hwang, G.-R., Yuen, J. G., & Ju, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041624 · Cited by 15
Christensen, I. E., Jyssum, I., Tveter, A. T., Sexton, J., Tran, T. T., Mjaaland, S., Kro, G. B., Kvien, T. K., Warren, D. J., Jahnsen, J., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02587-8 · Cited by 18
Chen, P., Bergman, P., Blennow, O., Hansson, L., Mielke, S., Nowak, P., Gao, Y., Söderdahl, G., Österborg, A., Smith, C. I. E., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105385 · Cited by 17
Zhang, C., & Yang, M. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116083 · Cited by 20
Nanobiotechnology-Enabled mRNA Stabilization
Xian, H., Zhang, Y., Yu, C., & Wang, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020620 · Cited by 21
Yonezawa, H., Ohmura, S., Ohkubo, Y., & Miyamoto, T. (2022) · Internal Medicine · doi:10.2169/internalmedicine.0257-22 · Cited by 18
Hill, J., Montross, D., & Ivarsson, M. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1113003 · Cited by 21
Self-citationInterfering with Host Proteases in SARS-CoV-2 Entry as a Promising Therapeutic Strategy
Müller, P., Maus, H., Hammerschmidt, S. J., Knaff, P. M., Mailänder, V., Schirmeister, T., & Kersten, C. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210526111318 · Cited by 19
The Many Faces of Innate Immunity in SARS-CoV-2 Infection
Hanan, N., Doud, R. L., Park, I.-W., Jones, H. P., & Mathew, S. O. (2021) · Vaccines · doi:10.3390/vaccines9060596 · Cited by 18
Wankhede, D., Grover, S., & Hofman, P. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.01.072 · Cited by 18
Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis
Lotan, I., Hellmann, M. A., Friedman, Y., et al. (2022) · Neuromuscular Disorders · doi:10.1016/j.nmd.2022.01.013 · Cited by 16
Jacobson, M. A., Zakaria, A., Maung, Z., Hart, C., McCalmont, T. H., Fassett, M. S., & Amerson, E. H. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab518 · Cited by 15
Sung, K., Chang, T.-E., Wang, Y., Lin, C., Chang, C., Hou, M., & Lu, C. (2022) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000682 · Cited by 17
Krekeler, C., Reitnauer, L. E., Bacher, U., Khandanpour, C., Steger, L., Boeckel, G. R., Klosner, J., Tepasse, P., Kemper, M., Hennies, M. T., et al. (2022) · Cancers · doi:10.3390/cancers14225512 · Cited by 16
Wegwarth, O., Mansmann, U., Zepp, F., Lühmann, D., Hertwig, R., & Scherer, M. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.56208 · Cited by 14
L’accès aux vaccins anti-COVID-19 dans un monde en crise : état des lieux et stratégies
OECD (2021) · Les réponses de l’OCDE face au coronavirus (Covid-19) · doi:10.1787/fe64d679-fr · Cited by 16
Feng, Y., Chen, J., Yao, T., Chang, Y., Li, X., Xing, R., Li, H., Xie, R., Zhang, X., Wei, Z., et al. (2021) · Infectious Diseases of Poverty · doi:10.1186/s40249-021-00924-2 · Cited by 22
Zhang, X., Xie, G., Ma, H., Ding, S., Wu, Y., Fei, Y., Cheng, Q., Huang, Y., & Wang, Y. (2023) · Biofabrication · doi:10.1088/1758-5090/acee21 · Cited by 18
Immune-mediated liver injury following COVID-19 vaccination
Schinas, G., Polyzou, E., Dimakopoulou, V., Tsoupra, S., Gogos, C. A., & Akinosoglou, K. (2023) · World Journal of Virology · doi:10.5501/wjv.v12.i2.100 · Cited by 18
SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19
Liang, H., Wu, Y., Yau, V., Yin, H.-X., Lowe, S., Bentley, R., Ahmed, M. A., Zhao, W., & Sun, C. (2022) · Vaccines · doi:10.3390/vaccines10091538 · Cited by 18
Sukik, L., Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Yassine, H. M., Thani, A. A. A., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.04.026 · Cited by 18
Sachak-Patwa, R., Byrne, H. M., Dyson, L., & Thompson, R. N. (2021) · Communications Medicine · doi:10.1038/s43856-021-00038-8 · Cited by 17
National survey on deceased donor organ transplantation during the COVID-19 pandemic in Japan
Ito, T., Kenmochi, T., Ota, A., Kuramitsu, K., Soyama, A., Kinoshita, O., Eguchi, S., Yuzawa, K., & Egawa, H. (2021) · Surgery Today · doi:10.1007/s00595-021-02388-1 · Cited by 17
Skowronski, D. M., Setayeshgar, S., Zou, M., Prystajecky, N., Tyson, J. R., Sbihi, H., Fjell, C. D., Galanis, E., Naus, M., Patrick, D. M., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac023 · Cited by 18
Edwards, D. K., & Carfí, A. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102214 · Cited by 19
Azzam, S. H., Mukari, A., Hamed, M., & Kridin, K. (2022) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.15251 · Cited by 16
Akelew, Y., Henok, A., Ebrahim, E., Atnaf, A., & Hailemichael, W. (2021) · Immunity Inflammation and Disease · doi:10.1002/iid3.573 · Cited by 19
Quality of T-Cell Response to SARS-CoV-2 mRNA Vaccine in ART-Treated PLWH
Tortellini, E., Zingaropoli, M. A., Mancarella, G., Marocco, R., Carraro, A., Jamhour, M., Barbato, C., Guardiani, M., Dominelli, F., Pasculli, P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314988 · Cited by 17
Emergency department–based COVID‐19 vaccination: Where do we stand?
Waxman, M., Moschella, P., Duber, H. C., Martin, D. R., Benzoni, T., Rothman, R. E., & Schechter‐Perkins, E. M. (2021) · Academic Emergency Medicine · doi:10.1111/acem.14261 · Cited by 16
Cell-Specific mRNA Therapeutics for Cardiovascular Diseases and Regeneration
Kishore, R., & Magadum, A. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11020038 · Cited by 22
Third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders
Lake, D. F., Roeder, A. J., González‐Moa, M. J., Koehler, M. A., Kaleta, E. J., Jasbi, P., Vanderhoof, J., McKechnie, D., Forman, J., Edwards, B. A., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00151-2 · Cited by 16
Shukla, P., Pandey, P., Prasad, B., Robinson, T., Purohit, R., D'Cruz, L. G., Tambuwala, M. M., Mutreja, A., Harkin, J., Singh, T., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab496 · Cited by 17
Costa, G. J., de Azevedo, C. R. A. S., Júnior, J. I. C., Bergmann, A. K., & Thuler, L. C. S. (2021) · Cancer · doi:10.1002/cncr.33832 · Cited by 14
mRNA vaccines engage unconventional pathways in CD8+ T cell priming
Jo, S., Li, L., Thakur, C., Telfer, K. A., Sultan, H., Ohara, R. A., He, M., Nam, G., Chen, J., Ou, F., et al. (2026) · Nature · doi:10.1038/s41586-026-10353-6 · Cited by 29
“…in a manner dependent on type I interferon. mRNA–LNP induction of cross-dressing might explain their ability to activate CD8 + T cells against antigens not encoded by the vaccine. mRNA vaccines delivered by LNPs were adopted for widespread use in response to the global SARS-CoV-2 pandemic 5–7 .”
Qin, S., Huang, H., Xiao, W., Chen, K., He, X., Tang, X., Huang, Z., Zhang, Y., Duan, X., Fan, N., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.010 · Cited by 16
Taheri, S. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03471-x · Cited by 16
Nicolaidou, V., Georgiou, R., Christofidou, M., Felekkis, K. N., Pieri, M., & Papaneophytou, C. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032957 · Cited by 23
Olayiwola, M. O., Alaje, A. I., Yunus, A. O., Adedokun, K. A., & Bashiru, K. A. (2024) · Results in Control and Optimization · doi:10.1016/j.rico.2024.100384 · Cited by 18
Mehrotra, M., Lim, E., Lamba, K., Kamali, A., Lai, K., Meza, E., Szeto, I., Robinson, P. V., Tsai, C., Gebhart, D., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac246 · Cited by 16
A general computational design strategy for stabilizing viral class I fusion proteins
Gonzalez, K. J., Huang, J., Criado, M. F., Banerjee, A., Tompkins, S. M., Mousa, J. J., & Strauch, E.-M. (2024) · Nature Communications · doi:10.1038/s41467-024-45480-z · Cited by 20
Brlić, P. K., Pavletić, M., Lerga, M., Krstanović, F., Matešić, M. P., Miklić, K., Malić, S., Mikša, L., Pajcur, M., Peruč, D., et al. (2022) · Viruses · doi:10.3390/v14091966 · Cited by 20
Lijeskić, O., Klun, I., Djaković, M. S., Gligorić, N., Štajner, T., Srbljanović, J., & Djurković–Djaković, O. (2021) · Vaccines · doi:10.3390/vaccines9091031 · Cited by 17
Yu, S., Chen, K., Fang, L., Mao, H., Lou, X., Li, C., & Zhang, Y. (2021) · Vaccines · doi:10.3390/vaccines9060588 · Cited by 19
Kirkpatrick, J. N., Swaminathan, M., Adedipe, A. A., Garcia-Sayan, E. D., Hung, J., Kelly, N., Kort, S., Nagueh, S. F., Poh, K. K., Sarwal, A., et al. (2023) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2023.08.020 · Cited by 15
VanBlargan, L. A., Adams, L., Liu, Z.-M., Chen, R. E., Gilchuk, P., Raju, S., Smith, B. K., Zhao, H.-Y., Case, J., Winkler, E. S., et al. (2021) · bioRxiv · doi:10.1101/2021.04.26.441501 · Cited by 15
The Big Potential of Small Particles: Lipid-Based Nanoparticles and Exosomes in Vaccination
Shimon, M. B., Shapira, S., Seni, J., & Arber, N. (2022) · Vaccines · doi:10.3390/vaccines10071119 · Cited by 20
The repeated setbacks of HIV vaccine development laid the groundwork for SARS-CoV-2 vaccines
Harris, J. E. (2022) · Health Policy and Technology · doi:10.1016/j.hlpt.2022.100619 · Cited by 18
Cytosolic Delivery of Small Protein Scaffolds Enables Efficient Inhibition of Ras and Myc
Chan, A., Wang, H. H., Haley, R. M., Song, C., Gonzalez-Martinez, D., Bugaj, L. J., Mitchell, M. J., & Tsourkas, A. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00798 · Cited by 15
Nanobodies: COVID-19 and Future Perspectives
Valenzuela, G., Miranda-Chacón, Z., Salinas-Rebolledo, C., Jara, R., Cuevas, A., Berking, A., & Rojas‐Fernández, A. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.927164 · Cited by 17
Fabrication of subunit nanovaccines by physical interaction
Chen, H., Liu, H., Liu, L., & Chen, Y. (2022) · Science China Technological Sciences · doi:10.1007/s11431-021-2011-7 · Cited by 17
Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity
Liao, H., Wu, W.-L., Chiang, C.-Y., Huang, M., Shen, K., Huang, Y., Wu, S., Liao, C., Chen, H., & Liu, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094902 · Cited by 15
Veenstra, J. J., Wang, J., McKinnon-Maksimowicz, K., Liu, T., Zuniga, B., Hamzavi, I. H., Zhou, L., & Mi, Q.-S. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220736 · Cited by 15
Mosconi, G., Fantini, M., Righini, M., Flachi, M., Semprini, S., Hu, L., Chiappo, F., Veterani, B., Ambri, K., Ferrini, F., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164723 · Cited by 15
COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy
Wolf, A. B., & Álvarez, E. (2021) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000001088 · Cited by 15
Kim, K. H., Bhujel, R., Maharjan, R., Lee, J. C., Jung, H. S., Kim, H. J., Kim, N. A., & Jeong, S. H. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.07.013 · Cited by 21
Simplified Mathematical Modelling of Uncertainty: Cost-Effectiveness of COVID-19 Vaccines in Spain
Marco-Franco, J., Barros, P. P., González-de-Julián, S., Sabat, I., & Vivas-Consuelo, D. (2021) · Mathematics · doi:10.3390/math9050566 · Cited by 17
Yong, S. J., Halim, A., Halim, M., Mutair, A. S. A., Alhumaid, S., AlSihati, J., Albayat, H., Alsaeed, M., Garout, M. A., Azmi, R. A., et al. (2022) · Vaccines · doi:10.3390/vaccines10071067 · Cited by 16
Wang, B., Zhao, J., Liu, S., Feng, J., Luo, Y., He, X., Wang, Y., Ge, F., Wang, J., Ye, B., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2079426 · Cited by 13
SARS-CoV-2 Omicron-specific mRNA vaccine induces potent and broad antibody responses in vivo
Fang, Z., Peng, L., Lin, Q., Ren, P., Suzuki, K., Xiong, Q., Clark, P., Lin, C.-X., & Chen, S. (2022) · bioRxiv · doi:10.1101/2022.02.14.480449
Lemgart, V. T., Sawyer, A. J., Kuhlman, W. A., Griset, A. P., Ali, M. M., Caron, A., Shah, D., Le, T. T., Strauss, L., Jiao, J., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.020 · Cited by 25
“17–19 The FDA has approved two intramuscular (i.m.)-delivered, LNP-based mRNA vaccines for coronavirus (COVID-19) 20,21 and LNP-mediated systemic delivery of siRNA for the treatment of hereditary transthyretin amyloidosis, 22 demonstrating the clinical impact and feasibility of an LNP-based approach for nucleic acid d…”
Race, trust, and COVID-19 vaccine hesitancy in people with opioid use disorder.
Sullivan, M. C., Mistler, C. B., Copenhaver, M. M., Wickersham, J. A., Ni, Z., Kim, R. S., & Shrestha, R. (2022) · Health Psychology · doi:10.1037/hea0001120 · Cited by 21
Rovida, F., Esposito, G. L., Rissone, M., Novelli, V., Cutti, S., Muzzi, A., Rona, C., Bertoli, E., Daglio, M., Piralla, A., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.06.028 · Cited by 17
Advances in vaccine development for Chlamydia trachomatis
Poston, T. B. (2024) · Pathogens and Disease · doi:10.1093/femspd/ftae017 · Cited by 23
New vector and vaccine platforms: mRNA, DNA, viral vectors
Hanke, T. (2022) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000763 · Cited by 18
Pu, J., He, X., Xu, W., Wang, C., Lan, Q., Hua, C., Wang, K., Lu, L., & Jiang, S. (2022) · Viruses · doi:10.3390/v14030489 · Cited by 17
Damasceno, D. H. P., Amaral, A. A., Silva, C. A., & Silva, A. C. S. E. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210902094254 · Cited by 17
Aging and Microbiome in the Modulation of Vaccine Efficacy
Kumar, M., James, M. M., Kumawat, M., Nabi, B., Sharma, P., Pal, N., Shubham, S., Tiwari, R. R., Sarma, D. K., & Nagpal, R. (2022) · Biomedicines · doi:10.3390/biomedicines10071545 · Cited by 15
Ajaimy, M., Liriano-Ward, L. E., Graham, J. A., & Akalin, E. (2021) · Kidney360 · doi:10.34067/kid.0002532021 · Cited by 15
Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes
Woodworth, K. E., Callaghan, N. I., & Huyer, L. D. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202508761 · Cited by 20
Visser, C., Biedermann, J. S., Nierman, M. C., van der Meer, F. J. M., Gulpen, A. J. W., Moors, Y. C. F., Cannegieter, S. C., Lijfering, W. M., Kruip, M. J. H. A., & Coalition, O. B. O. T. D. C. &. T. (2022) · Thrombosis and Haemostasis · doi:10.1055/s-0042-1742628 · Cited by 15
Mayer, L., Weskamm, L. M., Fathi, A., Kono, M., Heidepriem, J., Krähling, V., Mellinghoff, S. C., Ly, M. L., Friedrich, M., Hardtke, S., et al. (2024) · npj Vaccines · doi:10.1038/s41541-023-00801-z · Cited by 19
Fear of COVID-19 and Vaccine Hesitancy among Pregnant Women in Poland: A Cross-Sectional Study
Janik, K., Nietupska, K., Iwanowicz-Palus, G., & Cybulski, M. (2022) · Vaccines · doi:10.3390/vaccines10101700 · Cited by 19
Evaluating the Long-Term Efficacy of COVID-19 Vaccines
(2021) · doi:10.1101/2021.01.13.21249779 · Cited by 15
Bai, J., Chiba, A., Murayama, G., Kuga, T., Yahagi, Y., Tabe, Y., Tamura, N., & Miyake, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-24938-4 · Cited by 18
Myocarditis: causes, mechanisms, and evolving therapies
Kyaw, T. S., Drummond, G. R., Bobik, A., & Peter, K. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2193330 · Cited by 17
Incidence and management of the main serious adverse events reported after COVID ‐19 vaccination
Padilla‐Flores, T., Sampieri, A., & Vaca, L. A. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1224 · Cited by 20
Advanced Molecular Tweezers with Lipid Anchors against SARS-CoV-2 and Other Respiratory Viruses
Weil, T., Kirupakaran, A., Le, M., Rebmann, P., Mieres‐Pérez, J., Issmail, L., Conzelmann, C., Müller, J. A., Rauch‐Wirth, L., Gilg, A., et al. (2022) · JACS Au · doi:10.1021/jacsau.2c00220 · Cited by 17
Deng, S., Shao, H., Shang, H., Pang, L., Chen, X., Cao, J., Wang, Y., & Zhao, Z. (2024) · Vaccines · doi:10.3390/vaccines13010025 · Cited by 15
“Lipid nanoparticles (LNPs) have emerged as the most advanced drug delivery platforms and attracted extensive attention in mRNA delivery, particularly during the COVID-19 pandemic [3,4].”
Leonard, A. C., Weinstein, J. J., Steiner, P. J., Erbse, A. H., Fleishman, S. J., & Whitehead, T. A. (2022) · Protein Engineering Design and Selection · doi:10.1093/protein/gzac002 · Cited by 15
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.